Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.

Saturday, December 22, 2007 General News J E 4
MALVERN, Pa., Dec. 21 Solstice Neurosciences, Inc.("Solstice") announced the appointment of Dennis L. Smith as President andChief Executive Officer. He will also continue to serve as Chairman to itsBoard of Directors.

Mr. Smith brings unique specialty pharmaceutical industry experience andexpertise to Solstice that will be invaluable in providing guidance,leadership, and strategies for growth as the company continues to broaden itsproduct portfolio globally and map its strategy.

Mr. Smith has nearly 35 years of broad and global experience in thepharmaceutical industry and most recently served as President and ChiefExecutive Officer of INO Therapeutics LLC., a specialty pharmaceutical companywith strengths in development, marketing, and sales of critical care drugs anddrug/device combinations. Prior to INO, Mr. Smith spent 15 years with DuPontPharmaceutical Company, where he served as President of U.S. Operations,Executive Vice President of Europe, and Vice President and General Manager inCanada, among numerous other positions at DuPont Pharmaceuticals and DuPontMerck. Mr. Smith was also employed in management positions at BaxterInternational and Sandoz Pharmaceuticals (now Novartis). Mr. Smith is agraduate of Michigan State University and the Lake Forest Graduate School ofBusiness.

"I am excited to be joining Solstice at this time to work with themanagement team and the Board of Directors to help lead and guide ourcompany's future strategic direction," said Mr. Smith.

About Solstice Neurosciences, Inc.

Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceuticalcompany focused on the development, manufacturing, sales and marketing ofspecialty products. Solstice's first product, Myobloc(R) (Botulinum Toxin TypeB) Injectable Solution, represents the only botulinum toxin type B currentlyavailable to physicians and patients. MYOBLOC is sold in the United States andapproved in Canada. It is also distributed and sold in the EU as NeuroBloc.MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD)to reduce the severity of abnormal head position and pain associated with CD.For more information about Solstice Neurosciences, Inc.,

Myobloc(R) and NeuroBloc(R) are registered trademarks of SolsticeNeurosciences, Inc.

SOURCE Solstice Neurosciences, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Professional Networking Web Site,
Royal Philips Electronics to Acquire Respironics f...